BioVie (BIVI) Competitors $7.85 -1.75 (-18.23%) As of 03:39 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BIVI vs. ZURA, ONCY, QNCX, PYXS, BMEA, INCR, ABOS, IMUX, IKNA, and MNOVShould you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Zura Bio (ZURA), Oncolytics Biotech (ONCY), Quince Therapeutics (QNCX), Pyxis Oncology (PYXS), Biomea Fusion (BMEA), InterCure (INCR), Acumen Pharmaceuticals (ABOS), Immunic (IMUX), Ikena Oncology (IKNA), and MediciNova (MNOV). These companies are all part of the "pharmaceutical products" industry. BioVie vs. Its Competitors Zura Bio Oncolytics Biotech Quince Therapeutics Pyxis Oncology Biomea Fusion InterCure Acumen Pharmaceuticals Immunic Ikena Oncology MediciNova Zura Bio (NASDAQ:ZURA) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation. Does the media refer more to ZURA or BIVI? In the previous week, BioVie had 1 more articles in the media than Zura Bio. MarketBeat recorded 2 mentions for BioVie and 1 mentions for Zura Bio. Zura Bio's average media sentiment score of 1.71 beat BioVie's score of 0.30 indicating that Zura Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zura Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive BioVie 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend ZURA or BIVI? Zura Bio currently has a consensus price target of $14.33, indicating a potential upside of 1,179.76%. Given Zura Bio's higher probable upside, analysts clearly believe Zura Bio is more favorable than BioVie.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13BioVie 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 4.00 Which has preferable valuation and earnings, ZURA or BIVI? Zura Bio is trading at a lower price-to-earnings ratio than BioVie, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-1.60BioVieN/AN/A-$32.12M-$7.91-0.99 Which has more risk & volatility, ZURA or BIVI? Zura Bio has a beta of -0.1, suggesting that its stock price is 110% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Do insiders and institutionals have more ownership in ZURA or BIVI? 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 4.6% of BioVie shares are owned by institutional investors. 22.1% of Zura Bio shares are owned by company insiders. Comparatively, 2.4% of BioVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is ZURA or BIVI more profitable? Zura Bio's return on equity of -42.84% beat BioVie's return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -42.84% -35.22% BioVie N/A -100.88%-78.49% SummaryZura Bio beats BioVie on 8 of the 13 factors compared between the two stocks. Get BioVie News Delivered to You Automatically Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIVI vs. The Competition Export to ExcelMetricBioVieMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$145.77M$2.37B$5.45B$8.92BDividend YieldN/A1.78%5.22%4.00%P/E Ratio-0.998.8927.2720.07Price / SalesN/A663.55428.46118.22Price / CashN/A21.7726.2128.59Price / Book3.094.507.925.58Net Income-$32.12M$31.26M$3.17B$248.65M7 Day Performance748.64%5.30%4.33%7.15%1 Month Performance626.84%5.63%2.61%8.13%1 Year Performance1,819.29%8.72%34.78%21.59% BioVie Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIVIBioVie0.3704 of 5 stars$7.85-18.2%N/A+135.2%$145.77MN/A-0.9910ZURAZura Bio3.5019 of 5 stars$1.05flat$14.33+1,265.1%-67.5%$71.79MN/A-1.503Positive NewsGap UpONCYOncolytics Biotech1.6659 of 5 stars$0.77+3.0%$4.33+460.6%-12.5%$70.77MN/A-2.6730Gap DownQNCXQuince Therapeutics2.8921 of 5 stars$1.65+6.5%$8.00+384.8%+120.1%$70.48MN/A-1.1960PYXSPyxis Oncology1.2151 of 5 stars$1.10flat$9.00+718.2%-61.6%$68.14M$16.15M-0.6960Positive NewsBMEABiomea Fusion2.5595 of 5 stars$1.80-0.6%$21.40+1,088.9%-60.9%$68.01MN/A-0.5150INCRInterCureN/A$1.47-1.3%N/A-35.4%$67.90M$66.28M0.00350High Trading VolumeABOSAcumen Pharmaceuticals1.2512 of 5 stars$1.16+3.6%$6.33+446.0%-49.6%$67.84MN/A-0.6020IMUXImmunic2.9419 of 5 stars$0.70-0.4%$11.60+1,563.1%-32.5%$67.07MN/A-0.5770Positive NewsIKNAIkena Oncology2.3757 of 5 stars$1.34-1.5%$3.00+123.9%-19.9%$65.63M$9.16M-1.5670Positive NewsMNOVMediciNova1.8421 of 5 stars$1.31-1.5%$7.00+434.4%-10.6%$65.23M$1M-5.7010Gap Down Related Companies and Tools Related Companies Zura Bio Competitors Oncolytics Biotech Competitors Quince Therapeutics Competitors Pyxis Oncology Competitors Biomea Fusion Competitors InterCure Competitors Acumen Pharmaceuticals Competitors Immunic Competitors Ikena Oncology Competitors MediciNova Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIVI) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioVie Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioVie With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BIVI Stock Alerts